National Institute for Health and Welfare
Helsinki, Uusimaa, 00530, Finland
NCT Number: NCT01528007
The aim of this research is to explore the efficacy of the opiate antagonist, naltrexone as combined with CBT-intervention in the treatment of pathological gambling (PG). The study period is 2011-2014 during which one hundred Pathological Gamblers will be recruited to participate to this placebo-controlled double-blind trial.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Helsinki, Uusimaa, 00530, Finland
All participants have to be able to read and understand the patient information sheet and sign the informed consent. All participants are free to stop being in the study whenever they wanted. The patients are not paid or reimbursed for participation.
The study periods is 21 weeks during which the participant's have 8 appointments with the researchers. During the meetings research data will be collected and the participant is having Controlled Behavioral Therapy (CBT) consulting from a trained therapist. At the study visits, the subjects are given written instructions for the proper use of naltrexone and advised to take 50 mg naltrexone approximately one hour before gambling or feeling urges to gamble (and to refrain from taking naltrexone at other times). In this study the maximal daily dose is 50mg of naltrexone. The medication is free for the subjects.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Naltrexone 50mg when graving to gamble.
Placebo pill with no active ingredients.
Time frame: Up to 21 weeks.
The investigators will interview PG-YBOCS questionnaire from the participants.
Time frame: Up to 21 weeks.
The investigators will ask the participants to fill in AUDIT questionnaire.
Time frame: Up to 21 weeks.
The investigators will ask the participants to fill in RAND 36 questionnaire.
Finnish Institute for Health and Welfare
Other Gov
Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention - a Placebo Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02337634
Behavior, Disruptive, Impulse Control, and Conduct Disorders
Chicago, Illinois, United States
View Trial DetailsNCT01528982
Behavior, Disruptive, Impulse Control, and Conduct Disorders
Chicago, Illinois, United States
View Trial DetailsNCT01215357
Behavior, Disruptive, Impulse Control, and Conduct Disorders
Los Angeles, California, United States
View Trial DetailsNCT05506384
Behavior, Behavior, Addictive
Lund, Sweden
View Trial Details